• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
SNT

SYNTARA LIMITED - Charts / Financials

1.96% ! 2.6¢
Market Cap $41.67M  !
Healthcare Drug Manufacturers - Specialty & Generic
Add to My Watchlist

Syntara Limited (ASX:SNT), headquartered in Frenchs Forest, New South Wales, is a... Syntara Limited (ASX:SNT), headquartered in Frenchs Forest, New South Wales, is a clinical stage biotechnology company focused on developing novel therapies for fibrotic diseases and rare haematological disorders. The company targets extracellular matrix dysfunction using its expertise in amine oxidase chemistry and related technologies to create first-in-class therapies for blood cancers, inflammation, and fibrosis.More

Corporate Spotlight

Syntara Limited (ASX:SNT), headquartered in Frenchs Forest, New South Wales, is a clinical stage biotechnology company focused on developing novel therapies for fibrotic diseases and rare haematological disorders.
View the full Corporate Spotlight arrow Created with Sketch.

FDA greenlights Syntara’s Amsulostat Phase 2b
refresh Created with Sketch. REFRESH
Last update - 09.59am 11/05/2026 (20 minute delay) ?
Day
Open 2.6¢   Day High 2.6¢   Day Low 2.6¢
Daily Volume 656164
Bids   Sellers
Number Price Volume   Number Price Volume
0 2.6¢ 2076703   0 2.7¢ 2142697

Directors & Senior Management

Dr. Adam R. Craig Member of Clinical Advisory Board
Mr. Cameron David Billingsley General Counsel
Prof. Claire Harrison Member of Clinical Advisory Board
Dr. Dieter Hamprecht Head of Chemistry
Dr. Gaby Hobbs Member of Clinical Advisory Board
Mr. Gary Jonathan Phillips CEO, MD & Director
Dr. Jana Baskar Chief Medical Officer
Dr. John Mascarenhas Member of Clinical Advisory Board
Dr. Kathleen M. Metters Independent Non Executive Chair
Dr. Kevin Patrick Lynch Member of Clinical Advisory Board
Ms. Kristen Morgan Head of Medical & Regulatory Affairs - Alliance Management
Dr. Simon P. Green Independent Non-Executive Director
Mr. Timothy Luscombe CFO & Company Secretary
Mr. Waradana Malitha Hashan De Silva Non-Executive Director
Dr. Wolfgang G. Jarolimek Head of Drug Discovery

Data source: ADVFN

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
2.6¢ 		Change
0.001(1.96%) 		Mkt cap ! $41.67M
Open High Low Volume
2.6¢ 2.6¢ 2.6¢ 656.1K

Buyers (Bids)

Vol. Price($)
2076703 2.6¢
 

Sellers (Offers)

Price($) Vol.
2.7¢ 2142697
Last trade - 09.59am 11/05/2026 (20 minute delay) ?

Top Stories

Diablo Resources acquires historic high-grade Horn Silver Project in Utah

HotCopper's latest Watchlist, with Diablo CEO Lyle Thorne, talking about the company's new acquisition – the historic, high-grade Horn Silver.
'Swift progression': Power now seeking MRE baseline at Morro do Ferro after acquiring the asset last month Power Minerals has started maiden diamond drilling at Morro do Ferro, hot on the heels of the company's acquisition of the asset last month.
WATCH: HotCopper @ 2026 RIU Resources Round-Up − All our from-the-floor interviews HotCopper was at the RIU Resources Round-Up in Sydney, talking to all the ASX-listed companies over the three days in Darling Harbour.
Gold standard: Bison Resources the biggest CY26 ASX IPO story to watch For Bison Resources, things are coming naturally ⁠— and it’s becoming harder and harder to ignore the Australian gold explorer.
Introducing Kaoko Metals: A new high-grade copper play on the ASX The latest HotCopper Capital Compass, where we've spoken to Kaoko Metals CEO and MD Gerard O'Donovan about the explorer's ASX arrival.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.